A British Rheumatology Biology Society Rheumatoid Arthritis Registry study showed that patients exposed to anti-TNF therapy may have a reduced risk of colorectal cancer (hazard ratio, 0.52, 95%CI, 0.30–0.89) (Mercer et al., 2015). The gene discussed is TNF; the disease is colorectal cancer.